Table 2.

Coexistence of KRAS, CDKN2A, TP53, and SMAD4 alterations in pancreatic cancer

CategoryAutopsy patients (n = 79)Xenografts (n = 84)
One gene
KRAS1 (100%)
Two genes
KRAS/CDKN2A9 (64%)9 (75%)
KRAS/TP532 (14%)2 (17%)
CDKN2A/TP533 (21%)1 (8%)
Three genes
KRAS/CDKN2A/TP5325 (71%)33 (85%)
KRAS/CDKN2A/SMAD43 (9%)5 (13%)
KRAS/TP53/SMAD44 (11%)1 (2%)
CDKN2A/TP53/SMAD43 (9%)0
Four genes
KRAS/CDKN2A/TP53/SMAD429 (100%)33 (100%)